FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114242284> ?p ?o ?g. }

• W2114242284 abstract "Background: Metastatic head and neck cancer (HNC) remains poorly treatable and novel therapies are needed. We explored drug inhibition profiles in a large panel of head and neck cancer cell lines in order to select better therapies in the future and explore synergistic combinations. Methods: We measured the IC50 values of 23 clinically relevant small molecule inhibitors in 30 HNC cell lines by viability (resazurin). Hierarchical cluster analysis of single agent profiles was performed. Two cell lines were treated with combinations of two inhibitors to evaluate synergy via combinatorial index calculation (Chou). Signaling pathways were interrogated by immunoblot. Results: Single agents with a high degree of activity included bortezomib (lowest IC50 for SCC74: 15pM), dasatinib (HN13: 36pM), NVP‐BEZ235 (SCC74: 50pM). However cluster analysis did not show consistent groupings, but similar agents clustered together. In both cell lines investigated for synergy — combinations of MET inhibitors with agents blocking GSK3‐s, Proteasome, src, EGFR, and PKC‐β, as well as combinations of src inhibition with PI3K, HDAC, IGF1R, or PKC‐β inhibition showed strong synergy by CI values. In SCC58 (non‐HPV) inhibitors of EGFR, MET, IGF1‐R, and HIF1 synergized with each other or with src or PKC‐s inhibition. In OSCC3 (HPV(+) MET inhibition synergized with everolimus (mTOR) or NVP‐BEZ235 (PI3K/mTOR). Specific combinations with high degrees of synergy include: SU11274 (MET)/Erlotinib (EGFR): SCC58 CI50=0.29; OSCC3: CI50=0.53; PHA665752 (MET)/Bortezomib (Proteasome): OSCC3 CI50=0.41; IGF1‐R‐Inh./HIF1‐Inh.: SCC58 CI50=0.33; IGF1‐R‐Inh./Enzastaurin (PKC‐s): SCC58 CI50=0.15; Bortezomib (Proteasome)/Enzastaurin (PKC‐s): SCC58 CI50=0.38; Enzastaurin(PKC‐ss)/IGF‐R‐Inh.: OSCC3 CI50=0.72; Enzastaurin (PKC‐s):/SU11274 (MET): OSCC3 CI50=0.47; SB216763(GSK3‐s)/SU11274: OSCC3 CI50=0.52; Dasatinib (src)/Wortmannin (PI3K): OSCC3 CI50=0.64; SAHA/Dasatinib(src): OSCC3 CI50=0.58; SB216763 (GSK3‐s)/SU11274 (MET): OSCC3 CI50=0.5. Immunoblotting showed varying effects on several downstream signaling cascades. E.g. after combined treatment with PF‐2341066 and Enzastaurin p‐ERK signaling was reduced significantly more than after treatment with either agent alone. Conclusion: HNC cell lines show differential sensitivity to targeted agents and do not readily cluster based on drug inhibition. Nevertheless remarkable sensitivity in multiple cell lines was observed for certain inhibitors targeting src, the proteasome, and PI3K. Furthermore synergy was noted combining inhibitors of established targets in HNC (MET, EGFR, IGFR, and HIF1). Furthermore HPV‐infected cell lines appear to be sensitive to combined inhibition of MET and the downstream PI3K/Akt/mTOR pathway. We are in the process of investigating the underlying etiology of specific drug sensitivities. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A165." @default.
• W2114242284 created "2016-06-24" @default.
• W2114242284 creator A5003198411 @default.
• W2114242284 creator A5003826371 @default.
• W2114242284 creator A5025071833 @default.
• W2114242284 creator A5029699240 @default.
• W2114242284 creator A5036921326 @default.
• W2114242284 creator A5055939516 @default.
• W2114242284 creator A5065862352 @default.
• W2114242284 date "2009-12-10" @default.
• W2114242284 modified "2023-09-27" @default.
• W2114242284 title "Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines" @default.
• W2114242284 doi "https://doi.org/10.1158/1535-7163.targ-09-a165" @default.
• W2114242284 hasPublicationYear "2009" @default.
• W2114242284 type Work @default.
• W2114242284 sameAs 2114242284 @default.
• W2114242284 citedByCount "0" @default.
• W2114242284 crossrefType "proceedings-article" @default.
• W2114242284 hasAuthorship W2114242284A5003198411 @default.
• W2114242284 hasAuthorship W2114242284A5003826371 @default.
• W2114242284 hasAuthorship W2114242284A5025071833 @default.
• W2114242284 hasAuthorship W2114242284A5029699240 @default.
• W2114242284 hasAuthorship W2114242284A5036921326 @default.
• W2114242284 hasAuthorship W2114242284A5055939516 @default.
• W2114242284 hasAuthorship W2114242284A5065862352 @default.
• W2114242284 hasConcept C121608353 @default.
• W2114242284 hasConcept C126322002 @default.
• W2114242284 hasConcept C185592680 @default.
• W2114242284 hasConcept C2776364478 @default.
• W2114242284 hasConcept C2777478702 @default.
• W2114242284 hasConcept C2778087573 @default.
• W2114242284 hasConcept C2779438470 @default.
• W2114242284 hasConcept C502942594 @default.
• W2114242284 hasConcept C55493867 @default.
• W2114242284 hasConcept C62478195 @default.
• W2114242284 hasConcept C71924100 @default.
• W2114242284 hasConcept C86554907 @default.
• W2114242284 hasConcept C98274493 @default.
• W2114242284 hasConceptScore W2114242284C121608353 @default.
• W2114242284 hasConceptScore W2114242284C126322002 @default.
• W2114242284 hasConceptScore W2114242284C185592680 @default.
• W2114242284 hasConceptScore W2114242284C2776364478 @default.
• W2114242284 hasConceptScore W2114242284C2777478702 @default.
• W2114242284 hasConceptScore W2114242284C2778087573 @default.
• W2114242284 hasConceptScore W2114242284C2779438470 @default.
• W2114242284 hasConceptScore W2114242284C502942594 @default.
• W2114242284 hasConceptScore W2114242284C55493867 @default.
• W2114242284 hasConceptScore W2114242284C62478195 @default.
• W2114242284 hasConceptScore W2114242284C71924100 @default.
• W2114242284 hasConceptScore W2114242284C86554907 @default.
• W2114242284 hasConceptScore W2114242284C98274493 @default.
• W2114242284 hasLocation W21142422841 @default.
• W2114242284 hasOpenAccess W2114242284 @default.
• W2114242284 hasPrimaryLocation W21142422841 @default.
• W2114242284 hasRelatedWork W1597915316 @default.
• W2114242284 hasRelatedWork W1974847342 @default.
• W2114242284 hasRelatedWork W2014806585 @default.
• W2114242284 hasRelatedWork W2078176419 @default.
• W2114242284 hasRelatedWork W2080080809 @default.
• W2114242284 hasRelatedWork W2083818892 @default.
• W2114242284 hasRelatedWork W2145430926 @default.
• W2114242284 hasRelatedWork W2330722755 @default.
• W2114242284 hasRelatedWork W2562564284 @default.
• W2114242284 hasRelatedWork W2619034493 @default.
• W2114242284 hasRelatedWork W2728483795 @default.
• W2114242284 hasRelatedWork W2800112455 @default.
• W2114242284 hasRelatedWork W2886035837 @default.
• W2114242284 hasRelatedWork W2920961693 @default.
• W2114242284 hasRelatedWork W2956010433 @default.
• W2114242284 hasRelatedWork W2956072323 @default.
• W2114242284 hasRelatedWork W2974626429 @default.
• W2114242284 hasRelatedWork W3000195951 @default.
• W2114242284 hasRelatedWork W3082507598 @default.
• W2114242284 hasRelatedWork W2188862913 @default.
• W2114242284 isParatext "false" @default.
• W2114242284 isRetracted "false" @default.
• W2114242284 magId "2114242284" @default.
• W2114242284 workType "article" @default.